Shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) have earned a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.

Brokerages have set a 12-month consensus price target of $190.00 for the company and are anticipating that the company will post $0.55 EPS for the current quarter, according to Zacks. Zacks has also given Mesa Laboratories an industry rank of 109 out of 265 based on the ratings given to related companies.

Several equities analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of Mesa Laboratories from a “strong sell” rating to a “buy” rating and set a $167.00 target price on the stock in a report on Tuesday, October 3rd. BidaskClub lowered shares of Mesa Laboratories from a “sell” rating to a “strong sell” rating in a report on Saturday, August 12th. Finally, TheStreet lowered shares of Mesa Laboratories from a “b” rating to a “c+” rating in a report on Monday, July 31st.

Shares of Mesa Laboratories (MLAB) traded up 2.13% during mid-day trading on Wednesday, reaching $156.31. The company’s stock had a trading volume of 3,064 shares. Mesa Laboratories has a 1-year low of $109.14 and a 1-year high of $169.80. The company has a market capitalization of $588.51 million, a price-to-earnings ratio of 53.71 and a beta of 0.49. The firm’s 50 day moving average price is $142.34 and its 200-day moving average price is $141.46.

Mesa Laboratories (NASDAQ:MLAB) last announced its quarterly earnings results on Monday, July 31st. The medical instruments supplier reported $0.39 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.56 by ($0.17). The company had revenue of $22.67 million during the quarter, compared to analyst estimates of $22.90 million. Mesa Laboratories had a net margin of 11.31% and a return on equity of 16.58%. On average, analysts predict that Mesa Laboratories will post $2.74 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 15th. Investors of record on Thursday, November 30th will be issued a dividend of $0.16 per share. The ex-dividend date of this dividend is Wednesday, November 29th. This represents a $0.64 annualized dividend and a dividend yield of 0.42%. Mesa Laboratories’s payout ratio is 22.94%.

ILLEGAL ACTIVITY NOTICE: “Brokerages Anticipate Mesa Laboratories, Inc. (MLAB) to Announce $0.55 EPS” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/10/11/brokerages-anticipate-mesa-laboratories-inc-mlab-to-announce-0-55-eps.html.

In related news, Director H Stuart Campbell sold 2,000 shares of Mesa Laboratories stock in a transaction on Thursday, August 3rd. The shares were sold at an average price of $143.37, for a total transaction of $286,740.00. Following the transaction, the director now owns 49,976 shares in the company, valued at approximately $7,165,059.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 8,610 shares of company stock worth $1,176,809 in the last 90 days. Company insiders own 15.70% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the stock. Voya Investment Management LLC purchased a new stake in Mesa Laboratories during the 2nd quarter worth $221,000. Strs Ohio increased its stake in Mesa Laboratories by 5.6% during the 2nd quarter. Strs Ohio now owns 1,900 shares of the medical instruments supplier’s stock worth $272,000 after buying an additional 100 shares during the period. BT Investment Management Ltd purchased a new stake in Mesa Laboratories during the 2nd quarter worth $277,000. Spark Investment Management LLC purchased a new stake in Mesa Laboratories during the 2nd quarter worth $300,000. Finally, The Manufacturers Life Insurance Company increased its stake in Mesa Laboratories by 7.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,564 shares of the medical instruments supplier’s stock worth $367,000 after buying an additional 169 shares during the period. 67.02% of the stock is currently owned by hedge funds and other institutional investors.

About Mesa Laboratories

Mesa Laboratories, Inc is focused primarily on quality control products and services. The Company operates through four segments: Instruments, Continuous Monitoring, Biological Indicators and Cold Chain. The Instruments Division designs, manufactures and markets quality control instruments and disposable products.

Get a free copy of the Zacks research report on Mesa Laboratories (MLAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Mesa Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.